JHOP - December 2020 Vol 10, No 6

June 2020 Vol 10, No 3

Outcomes for Patients Receiving Ibrutinib with or without Antifungal Therapy

JHOP - December 2020 Vol 10, No 6 - Original Research

Kori Daniels, PharmD, BCOP; Arpita Gandhi, PharmD, BCOP; Locke Bryan, MD; Amber Clemmons, PharmD, BCOP

The Safety Profile of Mini-Dose Methotrexate for Graft-versus-Host Disease Prophylaxis: Is There a Place for Folinic Acid Rescue?

JHOP - December 2020 Vol 10, No 6 - Original Research

Loriel J. Solodokin, PharmD, BCOP; Amir Steinberg, MD, FACP; Erin Moshier, MS

Evaluation of Inpatient Oral Chemotherapy: An Academic Medical Center Experience

JHOP - December 2020 Vol 10, No 6 - Original Research

Vincent J. Cascone, PharmD, BCOP; Kane M. Hosmer, PharmD, BCOP; Zahra Mahmoudjafari, PharmD, BCOP; David W. Henry, MS, RPh, BCOP, FASHP; Dennis W. Grauer, MS, PhD

Vaccination Rates in Patients with Hematologic Cancers After Hematopoietic Stem-Cell Transplant: A Single-Center Retrospective Study

JHOP - December 2020 Vol 10, No 6 - Original Research

Hiba Ahmad, PharmD, BCOP; Sarah Perreault, PharmD, BCPS, BCOP; Dayna McManus, PharmD, BCPS-AQ ID; Francine Foss, MD; Iris Isufi, MD; Stuart Seropian, MD; Jeffrey Topal, MD

Desensitization Permits Continued Trastuzumab and Ado-Trastuzumab Emtansine Therapy After Hypersensitivity Reaction

JHOP - December 2020 Vol 10, No 6 - Case Reports

Anna Kempke, PharmD, BCOP, BCPS; Shawna Kraft, PharmD, BCOP; Mariana Castells, MD, PhD; Rajan Ravikumar, MD; Catherine Van Poznak, MD

HOPA 2020 Abstracts, Part IV

JHOP - December 2020 Vol 10, No 6 - HOPA Abstracts

Recent Cancer Drugs Approved by the FDA: September-December 1, 2020

JHOP - December 2020 Vol 10, No 6 - FDA Updates

Results 1 - 7 of 7